Larry Copeland, MD
Gynecologic Oncology · Hilliard, OHNPI 1477595510
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,020 of the $11,937 with a category attached, or 75.6%. 9 manufacturers reported payments, led by Myriad Genetic Laboratories, Inc. at 25.1% of the total. Reporting peaked in 2020 at $4,300 and has fallen 52.3% since, to $2,050 in 2025.
Across 13 payments — averaging $918.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$3K
- Immunocore Limited$3K
- Novocure Inc.$2K
- Merck$2K
- GSK$1K
- Genentech, Inc.$199
- plus $371 from 3 others
Across 1 payment — averaging $428.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$428
What the payments were for
- Consulting fees$9,02076%
- Speaking & faculty fees$2,00017%
- Food & beverage$9178%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 2 | $3,000 |
| Immunocore Limited | 2 | $2,885 |
| Novocure Inc. | 2 | $2,140 |
| Merck | 1 | $1,920 |
| GSK | 2 | $1,423 |
| Genentech, Inc. | 1 | $199 |
| Caris MPI, Inc. | 1 | $130 |
| Seagen Inc. | 1 | $129 |
| Eisai Inc. | 1 | $112 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myChoice CDx$3,000
- KIMMTRAK$2,800
- Oncology$2,140
- MI CANCER SEEK$130
- ZEJULA$123
How this compares
$11,937 in reported general payments places this provider in the 80th percentile of 62 gynecologic oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RubracaRucaparib Camsylate | 11 | $196,399 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Hilliard
- David OmalleyHilliard$650K
- Floortje BackesHilliard$181K
- Casey CosgroveHilliard$30K
- Robert NeffHilliard$15K
- Jeffrey FowlerHilliard$720
- Paulina HaightHilliard$117
- Thomas HerzogCincinnati$585K
- Adam WalterSylvania$137K
- Amanda JacksonCincinnati$92K
- Amelia JerniganCleveland$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.